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Introduction
Lung transplant is utilized as a last resort and can be an 
effective treatment for patients with end stage lung disease. 
The incidence of lung cancer in lung transplant recipients is 
higher than that in general population (1-5). Contributing 
factors include significant smoking history, which is 
commonly noted in patients with lung cancer. Chronic 
immunosuppressed status after transplant is also thought to 
be a contributing risk factor (6). As the number of patients 
undergoing lung transplantation is increasing, more 
bronchogenic carcinomas are being detected after lung 
transplantation. There is a paucity of literature regarding 
treatment outcomes among lung transplant survivors who 
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are diagnosed with lung cancer. As a result, there is a lack 
of consensus on the best treatment strategy for this rare 
population of patients.
We have conducted a retrospective review on a large 
cohort of lung transplant patients to identify the incidence 
and treatment outcomes after a lung cancer diagnosis 
among lung transplant recipients.
Methods
The Cleveland Clinic lung transplantation database was used 
to identify patients with lung cancer diagnosed at the time 
of or after lung transplant. Clinical information including 
demographics, underlying lung disease, type of transplant, 
immunosuppressive regimen, lung cancer pathologies, 
cancer-related treatment, response, and toxicities were 
retrospectively reviewed and collected. Survival time was 
calculated from the diagnosis of lung cancer to expiration or 
last date patient known to be alive. In patients who received 
chemotherapy for lung cancer, survival was also calculated 
from the initiation of chemotherapy to expiration or last 
known alive. The study was approved by the Institutional 
Review Board of Cleveland Clinic Foundation.
Results
Between 2005 and 2013, 847 patients underwent a single 
or bilateral lung transplant at Cleveland Clinic Foundation. 
Of these patients, 17 (2%) were diagnosed with lung cancer 
subsequent to the transplant and were included in the study. 
Patient demographics and transplant characteristics are 
shown in Table 1. Most of the patients were male (76%) and 
former smokers (88%). The median age at lung transplant 
was 61 (range, 48–70) years. The majority of patients had 
lung transplantation for interstitial lung disease with or 
without chronic obstructive pulmonary disease (COPD) 
(76%). Nearly half of the patients underwent bilateral lung 
transplant (47%).
Tumor location and histology
Eight cancers were detected in the explanted lung at the 
time of lung transplantation (47%), five were diagnosed in 
the remaining native lung (29%), and three cancers were 
later diagnosed in the transplanted (donor’s) lung (18%). 
One patient had lung cancer present as distant metastasis 
without an identified primary lesion (6%). Lung cancers 
detected in the native and transplanted lung were diagnosed 
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MMF + AZT 3 [18]
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€, Karnofsky Performance Scale (KPS). Data missing on seven 
patients at the time of transplant; ¥, Karnofsky Performance 
Scale. Data missing on two patients at second post-op visit 
after transplant; $, ILD, interstitial lung disease. Includes usual  
interstitial pneumonia (UIP), non-specific interstitial pneumonia  
(NSIP), with or without COPD. COPD, chronic obstructive  
pulmonary disease; MMF, mycophenolic acid; AZT, azathioprine.
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at a median of 26.7 months (range, 7.9 months–5.4 years) 
after the transplant. The majority of patients (n=11) had 
early stage disease (stage I/II) (64%), one patient had locally 
advanced stage IIIA (6%) and five (29%) were stage IV 
disease at the time of diagnosis. Most patients with early 
stage disease were detected in the explanted lung at the 
time of transplant (n=8/11), few in the transplanted lung 
(n=2/11), and only one patient in the native lung after a 
single transplant.
Non-small cell lung cancer (NSCLC), was more 
common (n=15, 88%) than small cell lung cancer (SCLC) 
(n=2, 12%). NSCLC histology included squamous cell 
carcinoma (n=6), adenocarcinoma (n=6), adenocarcinoma 
in situ (n=2), and pleomorphic NSCLC (n=1). Lung cancer 
characteristics and treatment outcomes are summarized in 
Tables 2 and 3.
Treatment with a curative intent
Overall 12 out of 17 patients had potential curable disease 
(stage I–IIIA) and except for one patient, who did not 
receive adjuvant chemotherapy for stage II disease, all 
others were treated with stage-appropriate treatment. 
Among 12 patients with potential curable disease, eight 
patients had cancer in explanted lung and did not receive 
adjuvant therapy if diagnosed with stage I disease (5/8 
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Neither 4 [25]









$, Distant metastatic disease at diagnosis without known 
lung lesion; ￠ , excluding patients with cancer in explanted 
lung; €, Eastern Cooperative Oncology Group Performance 
Status. Data missing on four patients at first oncology visit;  
¥, data missing on two patients. NSCLC, non-small cell lung 
cancer; CXT, chemotherapy; RT, radiation therapy; CR, com-
plete response; PR, partial response; SD, stable disease; PD,  
progression of disease.
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Table 3 Disease and treatment characteristics and outcome
No. Stage Histology Site of disease Oncologic treatment modality Chemo regimen No. of chemotherapy cycles Dose of chemotherapy Best response Dose of radiation Survival (months)
1 I Adeno Ex-lung No treatment – – – – – 18.8 (alive)
2 I Squamous Ex-lung CXT for mets, palliative RT Carboplatin/docetaxel 3 Unknown PD 25 Gy/5 fx 19.4
3 I Adeno Ex-lung No treatment – – – – – 23.3 ¥
4 I Adeno Ex-lung No treatment – – – – – 8.9 (alive)
5 I SCLC Tx-lung RT, CXT definitive Tx Carboplatin/etoposide 4 Unknown CR 50 Gy/5 fx 14.3 (alive)
6 I Adeno Ex-lung CXT for mets in Tx-lung 1st line: carboplatin/pemetrexed 4 Carboplatin AUC 5/pemetrexed 500 mg/m2 (C1),  
carboplatin AUC 4/pemetrexed 400 mg/m2 (C2–C4)
CR – 27.9
Pemetrexed maintenance 3 500 mg/m2 SD
7 II Squamous Ex-lung, LN CXT adjuvant 1st line: carboplatin/docetaxel 3 Carboplatin AUC 6/docetaxel 75 mg/m2 (C1),  
carboplatin AUC 5/docetaxel 75 mg/m2 (C2),  
carboplatin AUC 5/docetaxel 55 mg/m2 (C3)
SD – 24
2nd line: erlotinib (started when liver 
mets developed)
– 150 mg/daily PR
8 II Adeno in situ Ex-lung No treatment – – – – – 29.20 €
9 II Squamous Ex-lung, LN CXT adjuvant 1st line: carboplatin/docetaxel 3 Carboplatin AUC 5/docetaxel 37.5 mg/m2 (C1),  
carboplatin AUC 5/docetaxel 55 mg/m2 (C2),  
carboplatin AUC 5/docetaxel 75 mg/m2 (C3)
SD – 12.9 ₠
2nd line: carboplatin/etoposide 1 Unknown Unknown
10 II Squamous Tx-lung RT, CXT definitive Tx Carboplatin/docetaxel 1 Carboplatin AUC 6/docetaxel 75 mg/m2 PD 50 Gy/5 fx 3.2
11 II Adeno in situ Na-lung, LN Surgery for localized disease, 
CXT for mets later
1st line: carboplatin/pemetrexed 2 Unknown Unknown – 13.3
2nd line: erlotinib – Unknown PD
12 IIIA Squamous Na-lung, LN RT – – – – Unknown 9.4
13 IV Adeno Na-lung, LN, malignant pleural effusion No treatment – – – – – 2.7
14 IV Pleomorphic NSCLC LN, bone Palliative RT – – – – 20 Gy/5 fx 1.3
15 IV Adeno Na-lung, LN, bone CXT for mets Carboplatin/pemetrexed 3 Carboplatin AUC 5/pemetrexed 500 mg/m2 (C1),  
carboplatin AUC 5/pemetrexed 450 mg/m2 (C2),  
carboplatin AUC 5/pemetrexed 400 mg/m2 (C3)
PD – 4.7
16 IV SCLC Tx-lung, liver, bone CXT for mets Cisplatin/etoposide 6 Unknown PD – 9.8
17 IV Squamous Na-lung, LN, liver, bone CXT for mets Unclear agents Unknown Unknown PD – 2.1
¥, Patient died secondary to lung transplant rejection; €, sudden death of unknown cause; ₠, patient died secondary to sepsis. Adeno, adenocarcinoma; squamous, squamous cell carcinoma; SCLC, small cell lung cancer; adeno in situ, adenocarcinoma in situ; NSCLC, non-small cell 
lung cancer; Ex-lung, explanted lung; Tx-lung, transplanted lung; LN, lymph node; Na-lung, native lung remaining; CXT, chemotherapy; mets, metastases; RT, radiation therapy; AUC, area under the curve; C1/2/3/4, cycle 1/2/3/4; PD, progression of disease; CR, complete response; SD, 
stable disease; PR, partial response; fx, fractions.
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explanted lung cancers were stage I). Two of these patients 
with stage I disease in explanted lung later developed 
relapsed disease in their transplanted lung (40%) and at that 
point, both patients were treated with chemotherapy. One 
patient also received additional palliative radiation.
Curative oncologic treatment beyond removal of 
explanted lung in stage I disease was offered based on stage 
and site of disease, and included lobectomy, radiation, 
sequential radiation followed by chemotherapy, and 
adjuvant chemotherapy. Lobectomy was performed in a 
patient with T2N1M0, stage II lung cancer in remaining 
native lung; however, this patient developed metastases 
5 months later, and died 7 months after chemotherapy 
was initiated. Sequential radiation (50 Gy in 5 fractions) 
followed by chemotherapy was delivered to two patients 
with cancer in transplanted lung (one with stage I small cell 
lung cancer, and the other with stage II NSCLC disease). 
Adjuvant chemotherapy was administered in 2 out of 3 
patients with stage II disease in explanted lung.
Chemotherapy
Chemotherapy was given in 10/17 (59%) all patients, 
primarily carboplatin-based doublets (n=8), paired with 
docetaxel, pemetrexed, or etoposide.
Upfront chemotherapy in the form of adjuvant treatment 
or combined with radiation was offered in 40% of all 
chemotherapy-treated patients (4/10) and the remaining 
60% were treated with a palliative intent (6/10), half 
of whom were initially stage I or II at diagnosis. The 
remaining seven patients (41%) who were not treated with 
chemotherapy during their cancer treatment included four 
patients with early stage cancer in explanted lung (three 
with T1N0 stage I and one with T3N0 stage II), one patient 
with stage IIIA disease in remaining native lung treated with 
radiation alone, and two patients with stage IV metastatic 
disease.
Among patients with early stage disease (stage I–II, 
n=11), a total of seven patients received chemotherapy +/− 
radiation for either nodal involvement in the explanted 
lymph nodes (n=2), disease in the transplanted lung 
after bilateral transplant (n=2), or later, when metastases 
developed (n=3).
Among those patients who received chemotherapy 
with a palliative intent for metastatic disease (n=6), best 
radiographic response was progressive disease during 
treatment in three (50%) and not evaluable in two other 
patients (33%), however, one patient had a complete 
response 3 months after initiation of chemotherapy. 
Among patients with measurable disease who were given 
chemotherapy with curative intent (n=2), one had a 
complete response after sequential radiation followed by 
chemotherapy for SCLC, and the other had progression of 
disease as best response after receiving sequential radiation 
and chemotherapy for stage II squamous cell disease in 
transplanted lung.
Treatment outcome (Table 4)
Median survival from the diagnosis of lung cancer was 
better in patients who had cancer in the explanted lung than 
in those who developed cancer at a later date in the native 
or transplanted lungs: 24 months [confidence interval (CI), 
12.9–29 months] vs. 4.8 months (CI, 1.3–13.3 months). 
Unsurprisingly, median survival is also more favorable in 
stage I–IIIA (23.2 months; CI, 9.4–27.8 months) compared 
to stage IV disease (2.5 months; CI, 1.3–9.7 months).
Median survival of early stage patients (stage I–II) who 
received treatment was 14.3 months (range, 3.2–27.9 months). 
Two died of grade 5 neutropenia and sepsis at 3 and 13 
months after the diagnosis of cancer. Also of note, two 
patients had a complete response to first-line chemotherapy. 
One was still alive 14.3 months after cancer diagnosis 
(when data was collected). The other patient unfortunately 
developed lung rejection at which point chemotherapy had 
to be stopped, with a survival time of 27.9 months after the 
diagnosis of lung cancer, 10 months after the initiation of 
chemotherapy. Early stage patients without treatment (n=4) 
had a median survival of 21 months (range, 8.9–29.2 months), 
two of whom died of causes unrelated to lung cancer (one due 
to lung rejection, and one due to sudden death of unknown 
cause).
Median survival of patients with stage IV metastatic 
disease at diagnosis was 2.7 months (range, 1.3–9.8 months) 
and those who received chemotherapy had slightly longer 
survivals (2.1–9.8 months) compared to those who did 
not receive chemotherapy (1.3 and 2.7 months). Of those 
patients who received chemotherapy, best response was 
documented as progression of disease in two patients 
(survival 4.7, and 9.8 months from diagnosis), and early 
death secondary to sepsis after first cycle of chemotherapy 
in third patient (survival 2.1 months). Due to small number 
of patients (n=5), no direct statistical comparison was 
performed among patients treated with chemotherapy vs. 
best supportive care only.
Patients who later developed metastatic disease, however, 
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Table 4 Survival outcomes
Outcome No. death [%] Median survival months (95% CI)
Overall survival
Survival from transplant 14 [82] 23.6 (19.4–58.7)
Survival from lung cancer diagnosis 14 [82] 13.3 (2.8–24.0)
Survival from initiation of CXT 8 [89] 7.5 (0.3–20.6)
Survival from transplant
Unilateral 9 [100] 20.0 (12.9–70.0)
Bilateral 5 [62] 24.0 (NA)
Explanted lung 6 [75] 24.0 (12.9–29.0)
Native or transplanted lung 7 [88] 41.1 (17.7–77.6)
Survival from lung cancer diagnosis
Unilateral 9 [100] 9.7 (2.0–19.7)
Bilateral 5 [62] 23.6 (1.3–29.0)
Explanted lung 6 [75] 21.3 (8.9–29.2)
Native or transplanted lung 7 [87] 7.0 (2.1–14.3)
Stage-specific survival (ECOG)
I-III 9 [75] 23.2 (9.4–27.8)
IV 5 [100] 2.5 (1.3–9.7)
Performance-specific survival (ECOG) ￠
0–1 7 [78] 13.3 (2.0–27.8)
2–3 4 [100] 12.7 (1.3–19.7)
￠ , Eastern Cooperative Oncology Group Performance Status at the time of cancer diagnosis. CXT, chemotherapy; CI, confidence 
interval; NA, not available.
had a mixed response subsequent to chemotherapy. Three 
patients with early stage I–II who later developed metastasis 
were treated with chemotherapy. One patient with NSCLC 
had a complete response to therapy, but later discontinued 
continuous maintenance treatment due to transplant 
rejection. This patient lived to 10 months after initiation of 
chemotherapy (27.9 months since initial diagnosis of lung 
cancer). Another patient developed pancytopenia after two 
cycles of chemotherapy, did not have a formal response 
evaluation, and was switched to erlotinib. Unfortunately, 
this patient had progression of disease through erlotinib 
and lived for 5.5 months since starting systemic therapy 
(6.7 months since diagnosis of metastatic disease, 13.3 months 
from diagnosis of early stage lung cancer). The third patient 
had progression of disease as best response to chemotherapy 
with a poor survival since diagnosis of metastatic disease and 
initiation of chemotherapy (5.7 and 2.6 months, respectively; 
19.4 months overall survival since diagnosis of cancer). 
The initial gap between diagnosis of metastatic disease and 
initiation of systemic treatment in this patient was due to 
confirmation and palliative radiation to soft tissue.
In general, patients who received chemotherapy had a 
median survival of 7.5 months (95% CI, 0.3–20.6 months) 
from the initiation of chemotherapy. Anemia (30%) and 
fatigue (30%) were the most common toxicities, while 
sepsis was most severe and the cause of death in 30% of 
chemotherapy-treated patients (n=3/10).
Discussion
The reported rate of developing lung cancer after lung 
transplantation is 1.0–4.1% (1,3,4,7), much higher than 
that of 0.2% in the general population (5). The incidence 
of lung cancer in our cohort was 2%, which is in line with 
prior studies. Review of available literature shows lung 
cancer to be more commonly detected after single-lung 
transplantation compared to bilateral lung transplant. The 
incidence of developing lung cancer in patients with single 
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lung transplant is 6.9–9.8%, whereas that after bilateral 
lung transplant it is 0–1.8% (4,8). Most of the bronchogenic 
carcinomas were found in the native lung after single lung 
transplant (1,3,4,7-10). In contrast, in our study, only 
5 out of 17 cases developed cancer in native lung after 
single transplant; 3 of whom were detected at an advanced 
stage with metastases to bone (n=3) and liver (n=2). In 
comparison, our study identified a significant number of 
cancers detected in explanted lungs (n=8), all associated 
with early stage disease with a better prognosis [median 
survival 21 months (range, 8.9–29.2 months)] compared to 
cancer in the native or transplanted lung [median survival 
7.2 months (range, 2.1–14.3 months)]. The incidence of 
lung cancer detection in explanted lungs is 0.9% in our 
study population, which is again, in concordance with 
previous studies reporting an incidence of 0.8–2.0% of lung 
cancer found in explanted lungs (1,11).
Literature regarding the treatment of lung cancer 
in lung transplant recipients is scant. Treatment option 
for this group of patient is often limited given their 
immunosuppressive status and comorbidities. In our study, 
patients with advanced stage disease generally had poor 
survival regardless of chemotherapy. The longest surviving 
patient with stage IV upon diagnosis (survival 9.8 months 
from diagnosis) had small cell lung cancer and received 
chemotherapy with carboplatin/etoposide. The other four 
patients with metastatic disease at diagnosis had NSCLC 
with survival ranging between 1.3 to 4.7 months.
Patients who later developed metastatic disease, however, 
had a mixed response subsequent to chemotherapy. Three 
patients with stage I–II who later developed metastasis were 
treated with systemic therapy with best response measured 
as complete response in one, progression of disease in 
another, and not evaluable in the third case. The longest 
surviving patient was the one with complete response 
(10 months since initiation of chemotherapy) who eventually 
succumbed to transplant rejection rather than malignancy.
Overall, it appears that response to chemotherapy in the 
palliative setting is very low in this population, although 
occasional cases of complete response can be found. The 
more challenging aspect of treatment, however, remains the 
high toxicity rate with hematologic grade 4–5 events being 
common. Patients who were treated with chemotherapy 
numerically had a longer survival than those who were 
not treated, but it is difficult to control for the possible 
difference in comorbidities and performance in this 
retrospective review. In addition, it appears that patients 
who were initially diagnosed with early stage disease may 
have a better response to palliative chemotherapy when 
they develop metastasis compared to those with stage IV 
at diagnosis, however, risk of hematologic toxicities remain 
high in this population as well.
Patients with early stage disease detected in explanted 
lungs without nodal involvement had a reasonable survival 
without immediate additional treatment. Among five 
patients with stage I lung cancer discovered in explanted 
lung, two were alive at the time of data capture (9 and 
19 months since diagnosis of cancer), and remaining 
patients had lived a median survival of 23.3 months (range, 
19.4–27.9 months).
In addition, chemotherapy could be offered to those 
early stage patients with nodal involvement, those with 
disease in transplanted lung or remaining native lung 
after unilateral lung transplant, or patients with relapsed 
disease. Chemotherapy in this group results in higher 
rates of response and longer survival compared to those 
patients receiving therapy for stage IV disease. However, 
median survival in this group is numerically worse than 
those with stage I lung cancer in explanted lung, who did 
not receive chemotherapy. This difference to some extent 
reflects biologic and stage impact of nodal involvement in 
chemotherapy-treated group or comorbidities associated 
with cancer in remaining native or transplanted lung as 
compared to unexpected discovery of cancer in explanted 
lung without nodal involvement. It is also possible that 
some of the survival differences could be attributed to 
adverse events from chemotherapy, and particularly sepsis 
secondary to profound bone marrow suppression in this 
already immune-compromised population.
In summary, the possible survival advantages of 
chemotherapy must be weighed careful ly against 
serious adverse events. Patients with metastatic disease 
had a numerically longer survival when treated with 
chemotherapy, and there have been cases of complete 
response in our cohort  of  chemotherapy-treated 
patients. But chemotherapy-associated toxicities can 
also be detrimental in this group of patients, as 30% of 
chemotherapy-treated patients died of grade 5 sepsis. 
Therefore modified regimens with careful dose reduction 
along with bacterial and viral prophylaxis should be 
considered when treating this group of patients in order to 
decrease the risk of severe toxicities.
Conclusions
Lung cancer detected at the time of or after lung 
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transplantation carries various clinical courses. Patients 
with metastasis have poor survival and significant toxicities 
from chemotherapy, but variability in outcome still remains. 
Early stage patients and those with lung cancer in explanted 
lungs should be considered for treatment with a curative 
intent, but modified and dose-reduced regimens along with 
prophylactic antibiotics are highly encouraged to decrease 
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